Interpreting immunogenicity in oncology clinical trials

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immunogenicity of therapeutic proteins in oncology can lead to anti-drug antibodies (ADAs).
• ADAs can significantly affect drug pharmacokinetics, pharmacodynamics, efficacy, and safety.
• Assessing immunogenicity in oncology is complex due to assay sensitivity, drug interference, and patient sampling frequency.

Purpose of the Study:

• To review the background and nomenclature of immunogenicity assessment in oncology.
• To highlight the complexities and limitations in ADA detection and interpretation within oncology studies.
• To emphasize the clinical relevance of ADAs over their mere incidence.

Main Methods:

• Review of existing literature on immunogenicity in oncology clinical trials.
• Analysis of factors influencing ADA detection, including assay methods and sampling schedules.
• Discussion of patient-specific factors and concomitant treatments complicating data interpretation.

Main Results:

• Common nomenclature for immunogenicity has limitations in oncology.
• Clinical impact of ADAs is more critical than their presence alone.
• Interpretation challenges include patient factors, treatments, and survivorship bias.

Conclusions:

• Accurate interpretation of immunogenicity data requires consideration of assay methodology, study design, and sampling frequency.
• Clinicians must assess the clinical relevance of ADAs for informed treatment decisions.
• The focus in oncology should be on the clinical impact of ADAs, not solely their incidence.